Henry Schein today announced it has signed an agreement to acquire Acentus, a national medical supplier specializing in the delivery of Continuous Glucose Monitors (CGMs).
The Acentus transaction follows Henry Schein’s acquisition of Prism Medical Products in 2021 and Shield Healthcare and Mini Pharmacy in 2023, reinforcing the company’s strategic commitment to the homecare medical supplies market. Henry Schein’s homecare medical products platform will now have an annual revenue base of approximately $350 million.
Henry Schein expects the transaction to be neutral to 2024 non-GAAP earnings per share and accretive thereafter. Closing is subject to standard closing conditions and is expected to be completed in the first quarter of 2025. Financial terms were not disclosed.
“As the delivery of health care in the U.S. is increasingly provided in home-based settings, Henry Schein is strategically expanding our offerings to meet the growing demand,” said Stanley M. Bergman, Chairman of the Board and Chief Executive Officer, Henry Schein, Inc. “We are pleased to announce our acquisition of Acentus, which enhances our ability to deliver CGM products directly to patients’ homes. With Acentus, we will strengthen our position nationally in the home medical supply market and better serve our valued customers, including clinics, physician practices, health systems, ambulatory surgery centers, and most importantly, patients and families.”
Upon closing, Acentus Founders Brett Carroll, Todd Cianfrocca, Greg Duvall, and Julio Valdivia will join Henry Schein and bring their expertise and experience in the product category and the health care industry.
“We are delighted to partner with Henry Schein and further our efforts to provide accessible disposable medical supplies to the thousands of individuals nationwide who rely on these products to manage their chronic conditions,” said Mr. Cianfrocca, CEO of Acentus. “We are excited to contribute to the growth of Henry Schein’s emerging home health care business.”